<DOC>
	<DOCNO>NCT01140958</DOCNO>
	<brief_summary>Lung cancer No . cause cancer death Taiwan . Yet lung cancer diagnose late stage , amenable surgical resection . With introduction new target agent , EGFR tyrosine kinase inhibitor identification EGFR mutation , lung cancer management markedly change recent year . However , new agent costly payment restrict certain situation define National Insurance Agency . Therefore , use database National Insurance Agency might able reflect exact impact pharmacoeconomics . In study , investigator analyze data tertiary medical center , cost include insurance reimbursement , co-payment , payment cover insurance . The investigator also compare investigator result national database analyze cost benefit new agent lung cancer .</brief_summary>
	<brief_title>A Retrospective Pharmacoeconomic Study Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>lung cancer patient WanFang Hospital non</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>pharmacoeconomics</keyword>
	<keyword>new agent</keyword>
</DOC>